Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
CUMBERLAND PHARMACEUTICALS INC (CPIX)
|
Add to portfolio |
|
|
|
| Price: |
$3.12
| | Metrics |
| OS: |
14.4
|
M
| |
-5
|
% ROE
|
| Market cap: |
$44.8
|
M
| |
-12
|
% ROIC
|
|
Net cash:
|
$5.1
|
M
| |
$0.35
|
per share
|
|
EV:
|
$39.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$2.5
|
M
| |
15.7
|
x EV/EBITDA
|
|
EBIT
|
($2.0)
|
M
| |
|
|
| EPS |
($0.12)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 82.7 | 71.0 | 73.3 | 32.4 | 28.8 | 40.4 | 33.0 | 33.5 |
| Revenue growth | 16.4% | -3.1% | 126.1% | 12.5% | -28.7% | 22.3% | -1.5% | -9.2% |
| Cost of goods sold | 9.1 | 8.8 | 8.7 | 7.4 | 6.0 | 7.4 | 6.0 | 5.0 |
| Gross profit | 73.6 | 62.2 | 64.6 | 25.0 | 22.8 | 33.0 | 27.1 | 28.6 |
| Gross margin | 89.0% | 87.6% | 88.2% | 77.1% | 79.1% | 81.7% | 82.0% | 85.2% |
| Sales and marketing | 16.7 | 15.0 | 14.8 | 15.3 | 14.0 | 21.5 | 14.6 | 14.0 |
| Research and development | 6.7 | 5.7 | 5.8 | 6.9 | 7.6 | 4.3 | 3.2 | 3.8 |
| General and administrative | 10.2 | 9.8 | 10.2 | 10.0 | 10.2 | 9.7 | 8.6 | 7.6 |
| EBITA | 1.5 | -2.2 | -0.8 | -4.3 | -8.4 | -1.6 | 0.8 | 3.1 |
| EBITA margin | 1.8% | -3.0% | -1.1% | -13.4% | -29.2% | -4.1% | 2.3% | 9.3% |
| Amortization of intangibles | 5.1 | 4.4 | 4.4 | 4.1 | 2.8 | 2.4 | 2.2 | 2.0 |
| EBIT | -3.6 | -6.5 | -5.2 | -8.5 | -11.2 | -4.1 | -1.4 | 1.1 |
| EBIT margin | -4.4% | -9.2% | -7.1% | -26.2% | -38.8% | -10.1% | -4.3% | 3.3% |
| Pre-tax income | -5.6 | -5.6 | -6.6 | -9.3 | -10.8 | -3.9 | -1.3 | 1.2 |
| Income taxes | 0.1 | 0.0 | 0.1 | -0.1 | 0.0 | 4.2 | -0.3 | 0.6 |
| Tax rate | | | | 0.9% | | | 24.8% | 46.2% |
| Earnings from continuing ops | -5.6 | -11.1 | -13.2 | -18.4 | -21.6 | -8.0 | -0.9 | 0.7 |
| Earnings from discontinued ops | | 2.0 | 3.2 | 5.7 | 3.8 | | | |
| Net income | -5.6 | -9.1 | -10.0 | -12.7 | -17.8 | -8.0 | -0.9 | 0.7 |
| Net margin | -6.7% | -12.8% | -13.6% | -39.3% | -61.7% | -19.8% | -2.9% | 2.2% |
| |
| Diluted EPS | ($0.38) | ($0.74) | ($0.87) | ($1.20) | ($1.38) | ($0.50) | ($0.06) | $0.04 |
| Shares outstanding (diluted) | 14.6 | 14.9 | 15.2 | 15.4 | 15.6 | 15.9 | 16.2 | 17.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|